Drug intelligence / Profile preview

CognivAiD

Development stage: Unknown
Lead developer: Moleac
Administration: Oral

Overview

CognivAiD (MLC-SLT) is a Chinese Proprietary Medicine (CPM) developed by Moleac for the management of symptoms associated with vascular dementia. It is a multi-ingredient formulation derived from traditional medicine practices, designed to support cognitive function and address the neurodegenerative processes underlying vascular cognitive impairment. While the specific molecular targets are not fully defined due to its complex herbal composition, CognivAiD is characterized as having neuroprotective and neurorestorative properties. It is currently marketed in select regions as a therapeutic option for patients with vascular dementia, following the development model used by Moleac for its flagship neuro-restorative product, NeuroAiD.

Brand names: CognivAiD

Beyond the preview

Go deeper on CognivAiD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CognivAiD.

Explore the full profile